SAN DIEGO, CA - (NewMediaWire) - October 29, 2015 - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, has announced today the Company was added to OTCQB Venture Index (http://www.otcmarkets.com/index/.OTCQB/constituents).
The OTCQB Index is designed as a benchmark for tracking the overall performance of the OTCQB marketplace and serves primarily as a performance benchmark for investors in OTCQB securities. The index highlights entrepreneurial and development stage U.S. and international companies that have been verified to trade on OTCQB.
The addition of Innovus to the OTCQB Venture Index due to its increased trading volume and liquidity will enhance the Company's visibility to investors in the US Marketplace as the OTCQB is under a stricter market standards and eligibility requirements.
Dr. Bassam Damaj, Ph.D., President and Chief Executive Officer of Innovus Pharma, said, "We are extremely pleased that Innovus has been added to the OTCQB Venture Index. We believe the increased trading volume and liquidity of the stock is a very good sign of the Company's growing acceptance in the marketplace among investors leading to its addition to this Index. In addition, the Company is working diligently to up list to a higher exchange such as the NYSE or NASDAQ."
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com;www.myandroferti.com/
Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.